Successful treatment of a patient with mitochondrial myopathy with alirocumab |
| |
| Institution: | 1. Nijmegen Centre for Mitochondrial Disorders (NCMD), Amalia Children''s Hospital, Nijmegen, The Netherlands;2. Department of Biology, Darmstadt University of Technology, Darmstadt, Germany;3. Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK;4. Department of Pathology, Radboudumc, Nijmegen, The Netherlands;5. Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands;6. Department of Pathology, Antwerp University Hospital, Antwerp, Belgium;7. University of Antwerp, Antwerp, Belgium;1. Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China;2. Department of Pathology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China;3. Department and Institute of Cardiology, Zhongda Hospital, Southeast University, Nanjing 210009, China |
| |
| Abstract: | A 48-year-old man presented to our lipid clinic with statin intolerance and elevated serum creatine kinase levels, being affected by mitochondrial myopathy because of heteroplasmic mitochondrial DNA missense mutation in MTCO1 gene (m.7671T>A). He had just been treated with a coronary artery bypass 4 years before because of acute coronary syndrome, and he had consistently high levels of both low-density lipoprotein cholesterol and triglycerides. Dyslipidemia was successfully treated using 75 mg of alirocumab subcutaneously every 2 weeks, 10 mg of ezetimibe daily, 2 g of marine omega-3 fatty acids daily, and 145 mg of micronized fenofibrate every 2 days. Although muscle weakness persisted, myalgia did not reoccur and serum creatine kinase levels remained almost stable over the time. |
| |
| Keywords: | Mitochondrial myopathy Hypercholesterolemia PCSK9 inhibitor Alirocumab |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
